SARS-CoV-2 Vaccination-Induced Immunogenicity in Heart Transplant Recipients
Standard
SARS-CoV-2 Vaccination-Induced Immunogenicity in Heart Transplant Recipients. / Memenga, Felix; Kueppers, Simon Thomas; Borof, Katrin; Kirchhof, Paulus; Duengelhoef, Paul Maria; Barten, Markus Johannes; Lütgehetmann, Marc; Berisha, Filip; Fluschnik, Nina; Becher, Peter Moritz; Kondziella, Christoph; Bernhardt, Alexander M; Reichenspurner, Hermann; Blankenberg, Stefan; Magnussen, Christina; Rybczynski, Meike.
in: TRANSPL INT, Jahrgang 36, 06.02.2023, S. 10883.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - SARS-CoV-2 Vaccination-Induced Immunogenicity in Heart Transplant Recipients
AU - Memenga, Felix
AU - Kueppers, Simon Thomas
AU - Borof, Katrin
AU - Kirchhof, Paulus
AU - Duengelhoef, Paul Maria
AU - Barten, Markus Johannes
AU - Lütgehetmann, Marc
AU - Berisha, Filip
AU - Fluschnik, Nina
AU - Becher, Peter Moritz
AU - Kondziella, Christoph
AU - Bernhardt, Alexander M
AU - Reichenspurner, Hermann
AU - Blankenberg, Stefan
AU - Magnussen, Christina
AU - Rybczynski, Meike
N1 - Copyright © 2023 Memenga, Kueppers, Borof, Kirchhof, Duengelhoef, Barten, Lütgehetmann, Berisha, Fluschnik, Becher, Kondziella, Bernhardt, Reichenspurner, Blankenberg, Magnussen and Rybczynski.
PY - 2023/2/6
Y1 - 2023/2/6
N2 - Among heart transplant (HT) recipients, a reduced immunological response to SARS-CoV-2 vaccination has been reported. We aimed to assess the humoral and T-cell response to SARS-CoV-2 vaccination in HT recipients to understand determinants of immunogenicity. HT recipients were prospectively enrolled from January 2021 until March 2022. Anti-SARS-CoV-2-Spike IgG levels were quantified after two and three doses of a SARS-CoV-2 vaccine (BNT162b2, mRNA1273, or AZD1222). Spike-specific T-cell responses were assessed using flow cytometry. Ninety-one patients were included in the study (69% male, median age 55 years, median time from HT to first vaccination 6.1 years). Seroconversion rates were 34% after two and 63% after three doses. Older patient age (p = 0.003) and shorter time since HT (p = 0.001) were associated with lower antibody concentrations after three vaccinations. There were no associations between vaccine types or immunosuppressive regimens and humoral response, except for prednisolone, which was predictive of a reduced response after two (p = 0.001), but not after three doses (p = 0.434). A T-cell response was observed in 50% after two and in 74% after three doses. Despite three vaccine doses, a large proportion of HT recipients exhibits a reduced immune response. Additional strategies are desirable to improve vaccine immunogenicity in this vulnerable group of patients.
AB - Among heart transplant (HT) recipients, a reduced immunological response to SARS-CoV-2 vaccination has been reported. We aimed to assess the humoral and T-cell response to SARS-CoV-2 vaccination in HT recipients to understand determinants of immunogenicity. HT recipients were prospectively enrolled from January 2021 until March 2022. Anti-SARS-CoV-2-Spike IgG levels were quantified after two and three doses of a SARS-CoV-2 vaccine (BNT162b2, mRNA1273, or AZD1222). Spike-specific T-cell responses were assessed using flow cytometry. Ninety-one patients were included in the study (69% male, median age 55 years, median time from HT to first vaccination 6.1 years). Seroconversion rates were 34% after two and 63% after three doses. Older patient age (p = 0.003) and shorter time since HT (p = 0.001) were associated with lower antibody concentrations after three vaccinations. There were no associations between vaccine types or immunosuppressive regimens and humoral response, except for prednisolone, which was predictive of a reduced response after two (p = 0.001), but not after three doses (p = 0.434). A T-cell response was observed in 50% after two and in 74% after three doses. Despite three vaccine doses, a large proportion of HT recipients exhibits a reduced immune response. Additional strategies are desirable to improve vaccine immunogenicity in this vulnerable group of patients.
KW - Humans
KW - Male
KW - Middle Aged
KW - Female
KW - COVID-19 Vaccines
KW - BNT162 Vaccine
KW - COVID-19
KW - ChAdOx1 nCoV-19
KW - SARS-CoV-2
KW - Vaccination
KW - Antibodies, Viral
KW - Immunoglobulin G
KW - Heart Transplantation
KW - Transplant Recipients
U2 - 10.3389/ti.2023.10883
DO - 10.3389/ti.2023.10883
M3 - SCORING: Journal article
C2 - 36814697
VL - 36
SP - 10883
JO - TRANSPL INT
JF - TRANSPL INT
SN - 0934-0874
ER -